Spegra Tablet (30’s) is a combination medication designed to treat HIV-1 infection in adults and children. Each tablet contains three active ingredients: Dolutegravir (50mg), Emtricitabine (200mg), and Tenofovir Alafenamide (25mg). Dolutegravir is an integrase strand transfer inhibitor that prevents the integration of viral DNA into the host genome, while Emtricitabine and Tenofovir Alafenamide are nucleoside reverse transcriptase inhibitors that block reverse transcription, a crucial step in the HIV replication cycle. This powerful combination works synergistically to suppress viral load, improve immune function, and reduce the risk of HIV transmission. Spegra Tablet is typically prescribed as part of a comprehensive antiretroviral therapy regimen, and its formulation is designed to enhance patient adherence due to its once-daily dosing schedule. The drug is well-tolerated and has been shown to be effective in achieving and maintaining viral suppression, making it a vital option in the management of HIV.